Clinical trials for prostate cancer treatments are being closely monitored. Johnson & Johnson's Akeega trial focuses on a dual-action tablet, while Pfizer's trial investigates an EZH2 inhibitor. These studies aim to improve outcomes for patients with advanced prostate cancer.